The Hindu Business Line  Mar 15  Comment 
Investors with a short-term perspective can consider buying the stock of Natco Pharma at current levels. The stock encountered a key medium-term term resistance at around ₹1,050 in mid-January 2018
The Hindu Business Line  Mar 1  Comment 
Natco Pharma Ltd has filed an abbreviated new drug application (ANDA) for Sofosbuvir tablets with the United States Food and Drug Administration (USFDA), according to a company release issued here
The Hindu Business Line  Feb 6  Comment 
Natco Pharma net profit increased 11.85 per cent at ₹217 crore in the third quarter ended December 31, 2017, against ₹194 crore in the corresponding quarter of the previous year. Total revenue, how
The Hindu Business Line  Dec 16  Comment 
The Committee of Directors of Natco Pharma Limited has approved a move to raise about Rs 915 crore through qualified institutional placement. The committee, which met on Friday, approved the iss...
The Economic Times  Dec 14  Comment 
Specific details about utilisation of the proceeds were not disclosed.
The Hindu Business Line  Nov 14  Comment 
Sees advantage in new markets led by Hep C franchise products
The Hindu Business Line  Nov 7  Comment 
Natco Pharma has executed definitive agreement and subscribed to 7.50 per cent of the paid-up equity share capital of OMRV Hospitals Pvt Ltd (OMRV) at investment of ₹7.50 crore. OMRV operates unde...
The Hindu Business Line  Nov 4  Comment 
Natco Pharma today said it has invested Rs 7.5 crore to pick up 7.5 per cent stake in OMRV Hospitals. “NATCO Pharma Ltd would like to announce that today it has executed definitive agreement and su...
The Hindu Business Line  Nov 3  Comment 
Natco Pharma's marketing partner Alvogen has received final approval to market oseltamivir phosphate powder used for the treatment of influenza in the US. “Alvogen has received final approval and ...
The Hindu Business Line  Oct 5  Comment 
Natco Pharma stock gained as much as 32 per cent over the last two days after its marketing partner Mylan received approval from the US Food and Drug Administration (USFDA) for the generic version of...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki